Erinn Maury knew Remicade wasn’t the right drug for Patti Schulte, a rheumatoid arthritis patient the physician saw at her Millersville, Maryland, practice. Schulte’s swollen, painful joints hadn’t responded to Enbrel or Humira, two drugs in the same class.
Innovative malaria prodrug targets liver, enhances efficacy while reducing toxicity, preclinical studies show
Tafenoquine, a prodrug that could fulfill the criteria for a mass eradication campaign.